Search

Your search keyword '"Liu, Chen‐Hua"' showing total 707 results
Start Over Author "Liu, Chen‐Hua"
707 results on '"Liu, Chen‐Hua"'

101. Pegylated interferon-[alpha]-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infecion: a multicenter, randomized controlled trial

Author

Liu, Chen-Hua, Liu, Chen-Jen, Lin, Chih-Lin, Liang, Cheng-Chao, Hsu, Shih-Jer, Yang, Sheng-Shun, Hsu, Ching-Sheng, Tseng, Tai-Chung, Wang, Chia-Chi, Lai, Ming-Yang, Chen, Jun-Herng, Chen, Pei-Jer, Chen, Ding-Shinn, and Kao, Jia-Horng

Subjects
Interferon alfa-2a -- Dosage and administration, Interferon alfa-2a -- Research, Ribavirin -- Dosage and administration, Ribavirin -- Research, Hepatitis C -- Care and treatment, Drug therapy, Combination -- Research, Health, Health care industry
Published
2008

106. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Author

Liu, Chen-Hua, primary, Chen, Po-Yueh, additional, Chen, Jyh-Jou, additional, Lo, Ching-Chu, additional, Su, Wei-Wen, additional, Tseng, Kuo-Chih, additional, Liu, Chun-Jen, additional, Huang, Chia-Sheng, additional, Huang, Ke-Jhang, additional, Yang, Sheng-Shun, additional, Peng, Cheng-Yuan, additional, Tsai, Ming-Chang, additional, Kao, Wei-Yu, additional, Chang, Chi-Yang, additional, Shih, Yu-Lueng, additional, Fang, Yu-Jen, additional, Chen, Chi-Yi, additional, Lee, Pei-Lun, additional, Huang, Jow-Jyh, additional, Su, Pei-Yuan, additional, Tseng, Chi-Wei, additional, Hung, Chien-Ching, additional, Chang, Chung-Hsin, additional, Huang, Yi-Jie, additional, Lai, Hsueh-Chou, additional, Chang, Chun-Chao, additional, Lee, Fu-Jen, additional, Hsieh, Tsai‐Yuan, additional, and Kao, Jia-Horng, additional

Published
2021
Full Text
View/download PDF

107. Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load

Author

Tseng, Tai‐Chung, primary, Liu, Chun‐Jen, additional, Yang, Wan‐Ting, additional, Hsu, Chen‐Yang, additional, Hong, Chun‐Ming, additional, Su, Tung‐Hung, additional, Tsai, Cheng‐Hsueh, additional, Chen, Chi‐Ling, additional, Yang, Hung‐Chih, additional, Liu, Chen‐Hua, additional, Chen, Hsiu‐Hsi, additional, Chen, Pei‐Jer, additional, and Kao, Jia‐Horng, additional

Published
2021
Full Text
View/download PDF

108. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

Author

Liu, Chen-Hua, primary, Chen, Chi-Yi, additional, Su, Wei-Wen, additional, Tseng, Kuo-Chih, additional, Lo, Ching-Chu, additional, Liu, Chun-Jen, additional, Chen, Jyh-Jou, additional, Peng, Cheng-Yuan, additional, Shih, Yu-Lueng, additional, Yang, Sheng-Shun, additional, Huang, Chia-Sheng, additional, Huang, Ke-Jhang, additional, Chang, Chi-Yang, additional, Tsai, Ming-Chang, additional, Kao, Wei-Yu, additional, Fang, Yo-Jen, additional, Chen, Po-Yueh, additional, Su, Pei-Yuan, additional, Tseng, Chih-Wei, additional, Huang, Jow-Jyh, additional, Lee, Pei-Lun, additional, Lai, Hsueh-Chou, additional, Hsieh, Tsai-Yuan, additional, Chang, Chung-Hsin, additional, Huang, Yi-Jie, additional, Lee, Fu-Jen, additional, Chang, Chun-Chao, additional, and Kao, Jia-Horng, additional

Published
2021
Full Text
View/download PDF

111. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Author

Yu, Ming-Lung, Lee, Chuan-Mo, Chen, Chi-Ling, Chuang, Wan-Long, Lu, Sheng-Nan, Liu, Chen-Hua, Wu, Shun-Sheng, Liao, Li-Ying, Kuo, Hsing-Tao, Chao, You-Chen, Tung, Shui-Yi, Yang, Sien-Sing, Kao, Jia-Horng, Su, Wei-Wen, Lin, Chih-Lin, Yang, Hung-Chih, Chen, Pei-Jer, Chen, Ding-Shinn, and Liu, Chun-Jen

Published
2013
Full Text
View/download PDF

124. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Author

Yap, Desmond Y. H., primary, Liu, Kevin S. H., additional, Hsu, Yu-Chun, additional, Wong, Grace L. H., additional, Tsai, Ming-Chang, additional, Chen, Chien-Hung, additional, Hsu, Ching-Sheng, additional, Hui, Yee Tak, additional, Li, Michael K. K., additional, Liu, Chen-Hua, additional, Kan, Yee-Man, additional, Yu, Ming-Lung, additional, and Yuen, Man-Fung, additional

Published
2020
Full Text
View/download PDF

125. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)

Author

Tsai, Pei-Chien, primary, Chen, Chi-Yi, additional, Kuo, Hsing-Tao, additional, Hung, Chao-Hung, additional, Tseng, Kuo-Chih, additional, Lai, Hsueh-Chou, additional, Peng, Cheng-Yuan, additional, Wang, Jing-Houng, additional, Chen, Jyh-Jou, additional, Lee, Pei-Lun, additional, Chien, Rong-Nan, additional, Yang, Chi-Chieh, additional, Lo, Gin-Ho, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Yan, Sheng-Lei, additional, Bair, Ming-Jong, additional, Lin, Chun-Yen, additional, Su, Wei-Wen, additional, Chu, Cheng-Hsin, additional, Chen, Chih-Jen, additional, Tung, Shui-Yi, additional, Tai, Chi-Ming, additional, Lin, Chih-Wen, additional, Lo, Ching-Chu, additional, Cheng, Pin-Nan, additional, Chiu, Yen-Cheng, additional, Wang, Chia-Chi, additional, Cheng, Jin-Shiung, additional, Tsai, Wei-Lun, additional, Lin, Han-Chieh, additional, Huang, Yi-Hsiang, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chung, Wan-Long, additional, Ke, Chiao-Li Khale, additional, and Yu, Ming-Lung, additional

Published
2020
Full Text
View/download PDF

127. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations

Author

Yu, Ming-Lung, primary, Chen, Pei-Jer, additional, Dai, Chia-Yen, additional, Hu, Tsung-Hui, additional, Huang, Chung-Feng, additional, Huang, Yi-Hsiang, additional, Hung, Chao-Hung, additional, Lin, Chun-Yen, additional, Liu, Chen-Hua, additional, Liu, Chun-Jen, additional, Peng, Cheng-Yuan, additional, Lin, Han-Chieh, additional, Kao, Jia-Horng, additional, and Chuang, Wan-Long, additional

Published
2020
Full Text
View/download PDF

128. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Author

Yu, Ming-Lung, primary, Chen, Pei-Jer, additional, Dai, Chia-Yen, additional, Hu, Tsung-Hui, additional, Huang, Chung-Feng, additional, Huang, Yi-Hsiang, additional, Hung, Chao-Hung, additional, Lin, Chun-Yen, additional, Liu, Chen-Hua, additional, Liu, Chun-Jen, additional, Peng, Cheng-Yuan, additional, Lin, Han-Chieh, additional, Kao, Jia-Horng, additional, and Chuang, Wan-Long, additional

Published
2020
Full Text
View/download PDF

129. HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis

Author

Tseng, Tai-Chung, primary, Liu, Chun-Jen, additional, Chang, Crystal T., additional, Su, Tung-Hung, additional, Yang, Wan-Ting, additional, Tsai, Cheng-Hsueh, additional, Chen, Chi-Ling, additional, Yang, Hung-Chih, additional, Liu, Chen-Hua, additional, Chen, Pei-Jer, additional, Chen, Ding-Shinn, additional, and Kao, Jia-Horng, additional

Published
2020
Full Text
View/download PDF

130. High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy

Author

Chang, Wei-Yuan, primary, Chiu, Yen-Cheng, additional, Chiu, Fang-Wei, additional, Hsu, Yao-Chun, additional, Tseng, Tai-Chung, additional, Cheng, Pin-Nan, additional, Yang, Sheng-Shun, additional, Liu, Chun-Jen, additional, Su, Tung-Hung, additional, Yang, Hung-Chih, additional, Liu, Chen-Hua, additional, Chen, Pei-Jer, additional, Chen, Ding-Shinn, additional, and Kao, Jia-Horng, additional

Published
2020
Full Text
View/download PDF

134. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Huang, Chung-Feng, primary, Lai, Hsueh-Chou, additional, Chen, Chi-Yi, additional, Tseng, Kuo-Chih, additional, Kuo, Hsing-Tao, additional, Hung, Chao-Hung, additional, Wang, Jing-Houng, additional, Chen, Jyh-Jou, additional, Lee, Pei-Lun, additional, Chien, Rong-Nan, additional, Yang, Chi-Chieh, additional, Lo, Gin-Ho, additional, Tai, Chi-Ming, additional, Lin, Chih-Wen, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Yan, Sheng-Lei, additional, Bair, Ming-Jong, additional, Lin, Chun-Yen, additional, Su, Wei-Wen, additional, Chu, Cheng-Hsin, additional, Chen, Chih-Jen, additional, Tung, Shui-Yi, additional, Lo, Ching-Chu, additional, Cheng, Pin-Nan, additional, Chiu, Yen-Cheng, additional, Wang, Chia-Chi, additional, Cheng, Jin-Shiung, additional, Tsai, Wei-Lun, additional, Lin, Han-Chieh, additional, Huang, Yi-Hsiang, additional, Yeh, Ming-Lun, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Tsai, Pei-Chien, additional, Peng, Cheng-Yuan, additional, and Yu, Ming-Lung, additional

Published
2020
Full Text
View/download PDF

137. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy

Author

Tseng, Tai-Chung, primary, Peng, Cheng-Yuan, additional, Hsu, Yao-Chun, additional, Su, Tung-Hung, additional, Wang, Chia-Chi, additional, Liu, Chun-Jen, additional, Yang, Hung-Chih, additional, Yang, Wan-Ting, additional, Lin, Chia-Hsin, additional, Yu, Ming-Lung, additional, Lai, Hsueh-Chou, additional, Tanaka, Yasuhito, additional, Nguyen, Mindie H., additional, Liu, Chen-Hua, additional, Chen, Pei-Jer, additional, Chen, Ding-Shinn, additional, and Kao, Jia-Horng, additional

Published
2020
Full Text
View/download PDF

138. High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load

Author

Tseng, Tai-Chung, primary, Liu, Chun-Jen, additional, Hsu, Chen-Yang, additional, Hong, Chun-Ming, additional, Su, Tung-Hung, additional, Yang, Wan-Ting, additional, Chen, Chi-Ling, additional, Yang, Hung-Chih, additional, Huang, Yen-Tsung, additional, Fang-Tzu Kuo, Stephanie, additional, Liu, Chen-Hua, additional, Chen, Pei-Jer, additional, Chen, Ding-Shinn, additional, and Kao, Jia-Horng, additional

Published
2019
Full Text
View/download PDF

140. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.

Author

Su, Tung‐Hung, Yang, Hung‐Chih, Tseng, Tai‐Chung, Chou, Shih‐Wan, Lin, Chin‐Hsien, Liu, Chen‐Hua, Liu, Chun‐Jen, Chen, Chi‐Ling, Kao, Jia‐Horng, Su, Tung-Hung, Yang, Hung-Chih, Tseng, Tai-Chung, Chou, Shih-Wan, Lin, Chin-Hsien, Liu, Chen-Hua, Liu, Chun-Jen, Chen, Chi-Ling, and Kao, Jia-Horng

Abstract

Background: The risk of parkinsonism after antiviral treatment against chronic hepatitis C (CHC) is unclear.Objectives: To investigate the association between CHC and parkinsonism and the efficacy of antiviral therapy.Methods: Using the National Health Insurance Research Database of Taiwan from 2004 to 2012, patients with and without CHC, patients receiving pegylated interferon-based antiviral therapy, and those without such therapy were matched by age, gender, and comorbidities by propensity scores and followed for new diagnoses of parkinsonism and Parkinson's disease (PD). Multivariable Cox proportional hazards regression analyses were performed.Results: Overall, 49,342 patients with CHC were matched with 49,342 non-CHC patients. After adjustment for confounding factors, there was a significantly increased risk (31%) of parkinsonism (hazard ratio [HR] 1.306; 95% confidence interval [CI], 1.208-1.412) in those with CHC and the risk of parkinsonism requiring anti-Parkinson medication (HR 1.323; 95% CI, 1.214-1.441). Furthermore, 23,647 untreated CHC patients were matched with 23,647 patients receiving antiviral therapy. Patients receiving antiviral therapy had a significantly lower risk of developing parkinsonism (38%; HR 0.618; 95% CI, 0.498-0.765) and a reduced risk of parkinsonism requiring anti-Parkinson medication (HR 0.651; 95% CI, 0.515-0.823). In sensitivity analyses, antiviral therapy significantly reduced the risk of parkinsonism and PD after adjustment for detection, selection, disease latency biases, and competing mortality. Our results suggest successful antiviral therapy associates with a reduced risk of hepatitis C virus-related parkinsonism compared with those with treatment failure.Conclusions: CHC infection is associated with an increased risk of parkinsonism or PD. Antiviral therapy against CHC is associated with a reduced risk of parkinsonism or PD. © 2019 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

142. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.

Author

Liu, Chen‐Hua, Peng, Cheng‐Yuan, Kao, Wei‐Yu, Yang, Sheng‐Shun, Shih, Yu‐Lueng, Lin, Chin‐Lin, Tsai, Meng‐Kun, Lee, Chih‐Yuan, Chang, Chun‐Chao, Wu, Jo‐Hsuan, Liu, Chun‐Jen, Su, Tung‐Hung, Tseng, Tai‐Chung, Chen, Pei‐Jer, and Kao, Jia‐Horng

Subjects
*HEPATITIS C virus, *HEMODIALYSIS patients, *HEPATITIS C, *REINFECTION, *DISEASE risk factors
Abstract

Summary: Background: Data are limited regarding the risk of hepatitis C virus (HCV) reinfection after treatment‐induced sustained virologic response (SVR) in patients on haemodialysis. Aims: To assess the risk of HCV reinfection among patients on haemodialysis with treatment‐induced SVR. Methods: Patients on haemodialysis patients who achieved SVR12 with interferon (IFN) or direct‐acting antiviral (DAA)‐based treatment received follow‐up at SVR24 and then biannually with HCV RNA measurements. HCV reinfection was defined as the resurgence of viremia by different viral strains beyond SVR12. The low‐risk general population who achieved SVR12 and who underwent the same post‐SVR12 surveillance served as the reference group. Crude reinfection rates per 100 person‐years (PYs) were calculated. Multivariate Cox regression analysis was performed to estimate the relative risk of HCV reinfection between the two groups. Results: We recruited 374 patients on haemodialysis and 1571 reference patients with a mean post‐SVR12 follow‐up of 4.7 and 6.1 years. All haemodialysis patients who achieved SVR12 also achieved SVR24. The incidence rates of HCV reinfection were 0.23 per 100 PYs (95% confidence interval [CI]: 0.09‐0.59) in haemodialysis patients and 0.16 per 100 PYs (95% CI: 0.10‐0.26) in the reference group. The risk of HCV reinfection in patients on haemodialysis was comparable to that in the reference patients (hazard ratio [HR]: 1.39; 95% CI: 0.44‐4.38, P = 0.57). Conclusions: The risk of HCV reinfection in patients on haemodialysis who achieve SVR12 is low and comparable to that in the low‐risk general population. HCV microelimination in this special population is feasible once universal screening and scaled‐up treatment are implemented. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

149. Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

Author

Liu, Chen-Hua, Mücke, Marcus Maximilian, Maasoumy, Benjamin, Dietz, Julia, Mücke, Victoria Therese, Simon, Christian O., Canchola, Jesse, Cornberg, Markus, Marins, Ed G., Manns, Michael P., Zeuzem, Stefan, Wedemeyer, Heiner, Sarrazin, Christoph, Vermehren, Johannes, Liu, Chen-Hua, Mücke, Marcus Maximilian, Maasoumy, Benjamin, Dietz, Julia, Mücke, Victoria Therese, Simon, Christian O., Canchola, Jesse, Cornberg, Markus, Marins, Ed G., Manns, Michael P., Zeuzem, Stefan, Wedemeyer, Heiner, Sarrazin, Christoph, and Vermehren, Johannes

Abstract

Background: The COBAS AmpliPrep/COBAS TaqMan assay HCV (CAP/CTM) is widely used in clinical routine for HCV testing. Recently, the new cobas HCV test was established for high throughput testing with minimal operator intervention. As different assays may yield different quantitative/qualitative results that possibly impact treatment decisions, the aim of this study was to externally evaluate the cobas HCV test performance in comparison to CAP/CTM in a clinically relevant setting. Methods: Serum samples were obtained from 270 patients who received direct acting antiviral therapy with different treatment regimens at two study sites (Hannover and Frankfurt) in 2016. Overall, 1545 samples (baseline, on-treatment and follow-up) were tested in parallel by both assays. Results: The mean difference between cobas HCV and CAP/CTM for the quantification of HCV RNA was 0.008 log10 IU/ml HCV RNA (95% limits of agreement: -0.02–0.036) showing excellent agreement of both assays. With respect to clinical cut offs (HCV RNA detectable vs. target not detected and HCV RNA above the lower limit of quantification (LLOQ) vs.

Published
2019

150. Long‐term risk of end‐stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan.

Author

Hsieh, Meng‐Hsuan, Bair, Ming‐Jong, Tsai, Pei‐Chien, Tseng, Kuo‐Chih, Lo, Ching‐Chu, Chen, Chi‐Yi, Kuo, Hsing‐Tao, Hung, Chao‐Hung, Lai, Hsueh‐Chou, Peng, Cheng‐Yuan, Wang, Jing‐Houng, Chen, Jyh‐Jou, Lee, Pei‐Lun, Chien, Rong‐Nan, Yang, Chi‐Chieh, Lo, Gin‐Ho, Kao, Jia‐Horng, Liu, Chun‐Jen, Liu, Chen‐Hua, and Yan, Sheng‐Lei

Subjects
CHRONIC hepatitis C, CHRONIC kidney failure, CHRONIC hepatitis B, HEPATITIS C, HEPATITIS C virus, DIALYSIS (Chemistry), HEMODIALYSIS
Abstract

Background and Aim: Chronic hepatitis C virus (HCV) infection is associated with impaired renal function. The aim of this study is to explore the risk of and factors associated with end‐stage renal diseases (ESRD) under maintenance dialysis among HCV patients after anti‐HCV therapy. Methods: A total of 12 696 HCV‐infected patients with interferon‐based therapy, including 9679 (76.2%) achieving sustained virological response (SVR), were enrolled from 23 hospitals in Taiwan. Results: During a mean follow‐up period of 5.3 years (67 554 person‐years), the annual incidence of 4.1/10 000 person‐years, 4.0/10 000 and 4.7/10 000 person‐years among SVR patients and non‐SVR patients, respectively. History of diabetes and baseline estimated glomerular filtration rate < 60 mL/min/m2, instead of SVR, were the significant risk factors for developing ESRD with maintenance dialysis after anti‐HCV therapy (adjusted hazard ratio 7.75 and 9.78). Conclusion: Diabetes and baseline impaired renal function were strongly associated with progression to ESRD with maintenance dialysis among chronic HCV‐infected patients after antiviral therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results